Berberine

• Description:

  Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties. The sulfate form (HY-N0716B) improves bioavailability[1].

• Product Name Alternative:

  Natural Yellow 18

• UNSPSC:

  12352005

• Hazard Statement:

  H301-H315-H319-H335

• Target:

  Akt; Antibiotic; AP-1; Apoptosis; Autophagy; Bacterial; Caspase; JNK; NF-κB; Parasite; PI3K; Reactive Oxygen Species (ROS) ; Topoisomerase

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/berberine.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1

• Molecular Formula:

  C20H18NO4+

• Molecular Weight:

  336.36

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68 (1) :53-62.|[2]Cui HX, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24 (1) :103.|[3]Boberek JM, et al., Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010 Oct 29;5 (10) :e13745. |[4]Remppis A, et al., Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896.|[5]Bae J, et al., Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 2013 Feb;35 (2) :151-7. |[6]Ye Y, et al., Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Citation 01:

  Acta Pharmacol Sin. 2023 Feb;44 (2) :332-344.|Appl Biochem Biotechnol. 2024 Aug;196 (8) :5265-5282.|Aquaculture. 15 May 2022, 738055.|Biol Pharm Bull. 2022 Oct 1;45 (10) :1444-1451.|Biomed Pharmacother. 2024 Jan:170:116012.|BMC Pharmacol Toxicol. 2023 May 11;24 (1) :29.|Cell Stem Cell. 2025 May 1;32 (5) :778-794.e10.|Evid Based Complement Alternat Med. 2021 May 4:2021:6688629.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2024 May 13:114094.|Fish Shellfish Immunol. 2024 Jun:149:109522.|Food Chem Toxicol. 2023 May:175:113743.|Gene. 2022 Mar 30:816:146171.|Genome Instab Dis. 2025 Mar.|Hepatol Commun. 2024 Mar 29;8 (4) :e0405.|Int J Nanomedicine. 2023 Jul 31:18:4347-4363.|J Bone Miner Metab. 2021 Sep;39 (5) :748-756.|J Cell Mol Med. 2025 Sep;29 (17) :e70836.|J Ethnopharmacol. 2022 Mar 1:285:114786.|J Ethnopharmacol. 2024 Apr 24:324:117829.|J Inflamm Res. 2025 Aug 21:18:11451-11461.|J Pharm Pharmacol. 2022 Sep 1;74 (9) :1353-1363.|JCI Insight. 2023 Jul 24;8 (14) :e166306.|Microb Pathog. 2025 Dec:209:108114.|Mol Med Rep. 2023 Jan;27 (1) :17.|Mol Med. 2024 Dec 20;30 (1) :251.|Pharm Biol. 2024 Dec;62 (1) :53-61.|Phytomedicine. 2024 Jan:123:155247.|Phytomedicine. 2025 Sep 4:148:157233.|Res Sq. 2025 Apr 15.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Sep.|Sci Rep. 2022 Oct 17;12 (1) :17350.|Sci Rep. 2025 Jul 1;15 (1) :21623.|SSRN. 2023 Jan 27.|Toxicol Appl Pharmacol. 2025 Sep 13:505:117563.|Toxicol In Vitro. 2025 Dec:109:106128.|Acta Pharm Sin B. 2025 Jul 9.|Aquacult Nutr. 14 Jul 2022.|Biochem Pharmacol. 2021 Jun:188:114576.|Biochim Biophys Acta Mol Basis Dis. 2025 May 22:167920.|Cell Signal. 2025 Jul:131:111732.|Chin Med. 2025 Nov 17;20 (1) :190.|CNS Neurosci Ther. 2025 Feb;31 (2) :e70253.|Front Pharmacol. 2023 Apr 18:14:1148611.|Inflammopharmacology. 2024 May 17.|Int Immunopharmacol. 2024 May 29:136:112278.|Int Immunopharmacol. 2024 Sep 24;142 (Pt B) :113227.|Int J Biol Macromol. 2025 May 21:144496.|J Appl Toxicol. 2024 Nov;44 (11) :1700-1713.|J Food Biochem. 2025 Jul 16.|Mech Ageing Dev. 2020 Oct;191:111347.|Molecules. 2024 May 14.|Nat Commun. 2025 Jan 2;16 (1) :212.|Oncologie. 2023 Mar 10.|Phytomedicine. 2023 Sep:118:154962.|Phytomedicine. 2025 Apr:139:156517.|Research Square Preprint. 2021 May.|Research Square Print. 2022 Aug.|Cardiovasc Drugs Ther. 2022 Aug;36 (4) :633-643.|J Appl Microbiol. 2021 Apr;130 (4) :1154-1172.|Microbiol Spectr. 2023 Sep 25;11 (5) :e0217023.|NPJ Biofilms Microbiomes. 2025 Jul 1;11 (1) :120.|NPJ Sci Food. 2025 Feb 4;9 (1) :16.|Int Immunopharmacol. 2024 May 30:133:112036.|Mol Reprod Dev. 2024 Aug;91 (8) :e23768.|NPJ Sci Food. 2025 Feb 4;9 (1) :16.|Phytomedicine. 2024 Dec:135:156111.

• CAS Number:

  [2086-83-1]